Stocks and Investing
Stocks and Investing
Wed, February 5, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, February 4, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Anupam Rama Downgraded (VIR) to Hold and Increased Target to $26 on, Feb 4th, 2020
Anupam Rama of JP Morgan, Downgraded "Vir Biotechnology, Inc." (VIR) to Hold and Increased Target from $25 to $26 on, Feb 4th, 2020.
Anupam has made no other calls on VIR in the last 4 months.
There are 3 other peers that have a rating on VIR. Out of the 3 peers that are also analyzing VIR, 1 agrees with Anupam's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Madhu Kumar of "Baird" Initiated at Hold and Held Target at $17 on, Thursday, November 14th, 2019
These are the ratings of the 2 analyists that currently disagree with Anupam
- Paul Choi of "Goldman Sachs" Initiated at Strong Buy and Held Target at $37 on, Tuesday, November 5th, 2019
- Gena Wang of "Barclays" Initiated at Buy and Held Target at $25 on, Tuesday, November 5th, 2019